Research Summary
Dr. Gabrielson investigates the molecular biology of breast cancer and lung cancer, emphasizing aspects that have potential clinical significance. Current areas of emphasis include molecular classification of cancers, genetic instability in cancer, and functional changes in cancers related to cell-cell interactions and cellular metabolism.
Technology Expertise Keywords
Lung cancer; breast cancer; molecular biology; cell biology
Selected Publications
View all on PubMed
Li QK, Singh A, Biswal S, Askin F, Gabrielson E. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet; 56: 230-4, 2011
Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci U S A; 108: 5384-9, 2011
Lemmon, C. R., Woo, J. H., Tully, E., Wilsbach, K., and Gabrielson, E. Nuclear factor-kappaB (NF-kappaB) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase. J Biol Chem, 286: 31457-31465, 2011
Jhaveri TZ, Woo J, Shang X, Park BH and Gabrielson E. AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget. 2015; 6(17):14754-14765
Gniadek TJ, Li QK, Tully E, Chatterjee S, Nimmagadda S, Gabrielson E. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Mod Pathol. 2017;30:530-53
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.